跳至主要內容

Coverbase 推出保險業支援計劃 2023 名額 500 個

為協助保險業於後疫情時代運用金融科技發展業務，Coverbase 推出「保險業支援計劃 2023」，全數資助 Coverbase 「無限計劃」為期12個月的服務費用，價值 HKD $3,600。

計劃分兩階段進行審批，名額 500 個，如第一階段審批後尚有空缺，則會在第二階段繼續審批。

第一階段截止日期：2023年4月30日 (星期日)
第二階段截止日期：2023年6月30日 (星期五)

條款及細則
– 申請者必須為保險業或相關人士
– 申請者需要提供公司卡片核實
– 每人只限申請一個帳戶
– Coverbase 保留所有最終決定權

(需要登入 Google 帳戶以作上載公司卡片)

Coverbase 網址 : https://www.coverbase.io

此網誌的熱門文章

香港 Backlinks 網站， 中文本地 SEO 必備

市面上的 Backlinks 多數來自外國英文網站，對於香港網站未能精準地改善中文版 Google 排名，有見及此，有 IT 公司推出為香港公司而設的繁體中文 Backlinks 服務，在 100 多個高誠信度的新聞網站刊登文案，增加香港 Backlinks ，大大提升中文版 Google 排名。 新聞網站包括： https://www.buyinghongkong.com https://www.eatinghongkong.com https://www.playinghongkong.com https://www.relaxhongkong.com https://www.hk-bfn.com https://www.hk-cln.com https://www.hk-swn.com https://www.biznews.org.hk https://www.building.org.hk https://www.citylife.org.hk https://www.educate.org.hk https://www.healthy.org.hk https://www.hongkong.org.hk https://www.lohas.org.hk https://www.funding.org.hk https://www.tvp.org.hk https://www.bud.org.hk https://www.smefund.org.hk https://news.business138.com https://news.corporate138.com https://news.company138.com https://news.product138.com https://news.service138.com https://news.solution138.com https://news.website138.com https://news.supplier138.com https://news.vendor138.com https://news.directory138.com https://news.business228.com https:
閱讀更多

Hong Kong Science Park: Healthy ecosystem cultivates powerful global collaboration

(English) A healthy ecosystem cultivates powerful global collaboration   BeiGene, a global commercial-stage biotech company, has entered a worldwide strategic collaboration with our park company InnoRNA to take mRNA-based therapeutics to the next level. bit.ly/3yW8S0f You probably heard about Messenger RNA (mRNA). It has been used in some of the leading COVID vaccines. Q: What's mRNA's superpower? A: It directs human cells to generate proteins to help our immune systems develop antibodies for disease prevention and treatment. Q: What's InnoRNA's superpower? A: The platform developed by CEO Dr Li Linxian makes the mRNA less fragile, and the technology can rapidly and accurately identify safe and effective mRNA carriers for clinical treatment. Q: What's HKSTP's superpower? A: Hong Kong is the world's number two biotech funding hub.  We will leave you to find out more! Follow our page for more biotech news in Hong Kong and beyond. Reference : ht
閱讀更多

HKSTP Park Company Eurekabio has raised an RMB 100M+ Series B round to advance its automated cell processing platform

Congratulations! Eurekabio has raised an RMB 100M+ Series B round to advance its automated cell processing platform and the lentiviral vector production system developed by their team based at our Park.   Millions of people globally are suffering from different type of cancers. Our park company, Eurekabio, specialises in manufacturing supplies and platform for Cell and Gene Therapies (CGT).   Thank you Eurekabio for playing a pivotal role in accelerating the development of CGT through automation - Standardising cell processing procedures - Increasing efficiency - Reducing human error and contamination   Learn more: https://lnkd.in/gEGmc7Vz   Follow our page for more fundraising news happening in our thriving ecosystem. More Information : https://www.hkstp.org/what-we-offer/institute-for-translational-research-overview/
閱讀更多